胰高血糖素样肽1受体激动剂在肥胖型PCOS不孕患者中的应用进展  

Potential Application of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome and Infertile Patients with Obesity

作　　者：杨泽欣 王俊超(审校)[2] YANG Ze-xin;WANG Jun-chao(Graduate School,Tianjin Medical University,Tianjin 300070,China;Center of Reproductive Medicine,Tianjin Central Hospital of Gynecology Obstetrics,Tianjin 300100,China)

机构地区：[1]天津医科大学研究生院,300070 [2]天津市中心妇产科医院生殖医学中心

出　　处：《国际生殖健康／计划生育杂志》2021年第5期436-440,共5页Journal of International Reproductive Health/Family Planning

基　　金：天津市人类发育与生殖调控重点实验室开放基金项目(2019XH02)。

摘　　要：多囊卵巢综合征(polycystic ovary syndrome,PCOS)以高雄激素血症、稀发/无排卵、卵巢多囊样改变以及生育力下降为主要特征,是造成育龄期女性无排卵性不孕最常见的原因,且PCOS患者多伴有肥胖,而肥胖本身对女性生育力同样有负面影响。胰高血糖素样肽1(glucagon-like peptide-1,GLP-1)作为一种重要的胃肠激素,在肥胖以及PCOS进展中具有重要作用。综述肥胖/超重女性不孕以及PCOS发生机制,GLP-1在肥胖型PCOS女性中分泌模式的改变,以期为GLP-1受体激动剂(GLP-1 receptor agonists,GLP-1RA)在治疗肥胖型PCOS不孕患者中的应用提供理论支持。Polycystic ovary syndrome(PCOS)is characterized by hyperandrogenemia,oligo/anovulation,polycystic ovarian changes and impaired fertility.It is the most common cause of anovulatory infertility in women of childbearing age.Most of PCOS patients are accompanied by obesity,while obesity also has a negative impact on fertility.Glucagon-like peptide-1(GLP-1)as an important gastrointestinal hormone plays an important role in the obesity and progression of PCOS.This review summarizes the mechanism of PCOS and infertility with obese/overweight and the change of secretion pattern of GLP-1 in those PCOS women with obese.This review will provide the references that GLP-1 receptor agonists(GLP-1RA)can be used in the treatment of PCOS and infertile patients with obesity.

关 键 词：胰高血糖素样肽1 胰高血糖素样肽-1受体 多囊卵巢综合征 肥胖症 不育 女(雌)性 生殖技术 辅助 

分 类 号：R711.6[医药卫生—妇产科学]